Zymeworks Geçmiş Kazanç Performansı
Geçmiş kriter kontrolleri 0/6
Zymeworks has been growing earnings at an average annual rate of 21.8%, while the Biotechs industry saw earnings growing at 19% annually. Revenues have been growing at an average rate of 37.8% per year.
Anahtar bilgiler
21.8%
Kazanç büyüme oranı
28.8%
EPS büyüme oranı
Biotechs Sektör Büyümesi | 17.0% |
Gelir büyüme oranı | 37.8% |
Özkaynak getirisi | -31.0% |
Net Marj | -182.8% |
Son Kazanç Güncellemesi | 30 Sep 2024 |
Yakın geçmiş performans güncellemeleri
Recent updates
Zymeworks Inc. (NASDAQ:ZYME) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Nov 03Time To Worry? Analysts Are Downgrading Their Zymeworks Inc. (NASDAQ:ZYME) Outlook
Nov 01Zymeworks Approaching A Moment Of Truth With Zanidatamab
Sep 27Analysts Are Betting On Zymeworks Inc. (NASDAQ:ZYME) With A Big Upgrade This Week
Aug 07Zymeworks Inc.'s (NASDAQ:ZYME) 27% Share Price Surge Not Quite Adding Up
Jul 26Zymeworks: A Somewhat Complicated Story
Jul 09Zymeworks (NASDAQ:ZYME) Is In A Good Position To Deliver On Growth Plans
Jun 12Zymeworks Inc.'s (NASDAQ:ZYME) Shares Lagging The Industry But So Is The Business
May 03Buy Zymeworks Pioneering Cancer Treatments: Zanidatamab's Promising Data
Apr 18Zymeworks: A Strong Buy Amidst Zanidatamab's Promising Developments
Mar 05Zymeworks: Key Readout For Zanidatamab This Year And ADC Pipeline Expansion
Feb 06Zymeworks: Stock Emerges From Nearly 2 Years In The Doldrums, Thanks To An ADC Tailwind
Jan 31Zymeworks Non-GAAP EPS of -$0.66 beats by $0.31, revenue of $2.6M misses by $1.95M
Nov 08Zymeworks: A Binary Event With BTC Data By End-2022 Which May Trigger Milestone
Oct 26Zymeworks: A Roller Coaster Year
Jul 26Zymeworks And The Blue Falcon Elucidation
May 17Gelir ve Gider Dağılımı
Zymeworks nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.
Kazanç ve Gelir Geçmişi
Tarih | Gelir | Kazançlar | G+A Giderleri | Ar-Ge Giderleri |
---|---|---|---|---|
30 Sep 24 | 62 | -114 | 60 | 0 |
30 Jun 24 | 63 | -113 | 63 | 0 |
31 Mar 24 | 50 | -126 | 69 | 0 |
31 Dec 23 | 76 | -119 | 70 | 0 |
30 Sep 23 | 462 | 205 | 87 | 0 |
30 Jun 23 | 448 | 186 | 86 | 0 |
31 Mar 23 | 446 | 173 | 80 | 0 |
31 Dec 22 | 412 | 124 | 75 | 0 |
30 Sep 22 | 30 | -224 | 49 | 0 |
30 Jun 22 | 32 | -237 | 49 | 0 |
31 Mar 22 | 28 | -240 | 53 | 0 |
31 Dec 21 | 27 | -212 | 42 | 0 |
30 Sep 21 | 22 | -211 | 50 | 0 |
30 Jun 21 | 21 | -223 | 56 | 0 |
31 Mar 21 | 31 | -194 | 49 | 0 |
31 Dec 20 | 39 | -181 | 55 | 0 |
30 Sep 20 | 25 | -215 | 72 | 0 |
30 Jun 20 | 30 | -173 | 63 | 0 |
31 Mar 20 | 26 | -163 | 62 | 0 |
31 Dec 19 | 30 | -145 | 63 | 0 |
30 Sep 19 | 57 | -64 | 40 | 0 |
30 Jun 19 | 51 | -52 | 36 | 0 |
31 Mar 19 | 65 | -29 | 31 | 0 |
31 Dec 18 | 53 | -37 | 30 | 0 |
30 Sep 18 | 74 | -13 | 28 | 0 |
30 Jun 18 | 72 | -11 | 26 | 0 |
31 Mar 18 | 52 | -16 | 19 | 0 |
31 Dec 17 | 52 | -11 | 18 | 0 |
30 Sep 17 | 4 | -55 | 19 | 0 |
30 Jun 17 | 6 | -51 | 16 | 0 |
31 Mar 17 | 11 | -47 | 17 | 0 |
31 Dec 16 | 11 | -34 | 13 | 0 |
30 Sep 16 | 10 | -30 | 9 | 0 |
31 Dec 15 | 10 | -19 | 5 | 0 |
31 Dec 14 | 2 | -13 | 4 | 0 |
Kaliteli Kazançlar: ZYME is currently unprofitable.
Büyüyen Kar Marjı: ZYME is currently unprofitable.
Serbest Nakit Akışı ve Kazanç Analizi
Geçmiş Kazanç Büyüme Analizi
Kazanç Eğilimi: ZYME is unprofitable, but has reduced losses over the past 5 years at a rate of 21.8% per year.
Büyüme Hızlandırma: Unable to compare ZYME's earnings growth over the past year to its 5-year average as it is currently unprofitable
Kazançlar vs. Sektör: ZYME is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).
Özkaynak Getirisi
Yüksek ROE: ZYME has a negative Return on Equity (-30.97%), as it is currently unprofitable.